Pular para o conteúdo principal
Ranking Invest

FOLD - Amicus Therapeutics, Inc.

Segmento: HealthcareAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Análise Ranking Invest

Valuation estimado
-$ 413.24 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 193.56 Mi

Dívida Líquida

$ 261.81 Mi

L4T

-$ 29.37 Mi

MM4T

-6.15%

Indicadores Básicos

ROE

-15.18%

Índices de Previsibilidade

Receita Líquida

D0.08

Lucro

D0.53

Margem

D0.88

Índices de Tendência

Receita Líquida

A10.91

Lucro

A9.31

Margem

A10.05

Índices de Endividamento

DIV/PAT

1.35

DIV/L4T

-8.91

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.